Use of parasites and extracellular vesicles obtained from parasites in cancer treatment

A pharmaceutical composition for cancer treatment, wherein the composition comprises extracellular vesicles isolated from Leishmania infantum, wherein the extracellular vesicles are isolated from the Leishmania infantum via two-phase liquid system comprising following steps:

• collecting a culture media of the Leishmania infantum parasite, wherein the extracellular vesicles are isolated from the parasite,
• centrifuging at a rate of 2,000 g to 10,000 g for 5-20 minutes for a removal of undesirable substances such as cell residues and the parasite from the culture media,
• removing particles of size 220 nm and above by a filtration after a centrifugation,
• transferring a vesicle-protein mixture obtained by the centrifugation into the ATPS containing a PEG phase and a DEX phase for separation f the vesicle-protein mixture,
• removing non-vesicular proteins, a cello fat and other impurities from the extracellular vesicles by utilizing a chemical tendency of the PEG phase to the non-vesicular proteins and the DEX phase to phospholipid structured membranes,
• obtaining isolated extracellular vesicles.